SCHEMBL31349609

SCHEMBL31349609

CC(C)(CO)n1cnc2cc(B3OC(C)(C)C(C)(C)O3)cc(C(F)(F)F)c21

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31698989 0.78 AAK1 (0.32) FFAR1
SCHEMBL31349659 0.77 ESR2 (0.33) —
SCHEMBL31349605 0.76 HCAR1 (0.33) —
SCHEMBL31349447 0.70 USP30 (0.42) —
SCHEMBL31349536 0.69 MAP3K12 (0.32) —
SCHEMBL31349450 0.68 ABL1 (0.36) —
SCHEMBL14314217 0.68 LPL (0.34) FFAR1
SCHEMBL25313152 0.67 DGAT1 (0.36) FFAR1
SCHEMBL29197191 0.66 LPL (0.36) FFAR1
SCHEMBL21871238 0.65 TRPA1 (0.37) FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743078-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-20 — — EP disclosed
EP-4743079-A2 APOL1 INHIBITORS AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2026-05-20 — — EP disclosed
WO-2025015106-A2 APOL1 INHIBITORS AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2025-01-16 — — WO disclosed
WO-2025015104-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2025-01-16 — — WO disclosed
Send feedback